{"type":"trials","record":{"id":41451,"source_id":"clinicaltrials-gov","external_id":"NCT06843499","title":"Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening","brief_summary":"This study aims to evaluate the effectiveness of an artificial intelligence (AI)-assisted screening system in ophthalmic diagnosis. Using AI-based fundus photography, the system will assist physicians in diagnosing three common eye diseases: age-related macular degeneration and diabetic retinopathy (DR). The AI system will analyze fundus images from participants and rapidly generate detection results for ophthalmologists' reference in making final diagnoses and clinical decisions. The study will assess the clinical benefits of the AI-assisted diagnostic system, providing scientific evidence to enhance the efficiency of ophthalmic disease diagnosis and treatment.","overall_status":"Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"National Taiwan University Hospital","enrollment":1000,"countries":["Taiwan"],"start_date":"2025-06-02","completion_date":"2027-12-31","last_update_date":"2026-07-22","source_url":"https://clinicaltrials.gov/study/NCT06843499","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"20 Years","comparator":null,"organization":"National Taiwan University Hospital","interventions":["The VeriSee AI-assisted diagnostic system","Data collection from the patient's clinical history"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Sensitivity — From screening to physician-confirmed diagnosis of AMD or DR, an average of 1 month","Specificity — From screening to physician-confirmed diagnosis of AMD or DR, an average of 1 month","Concordance — From screening to physician-confirmed diagnosis of AMD or DR, an average of 1 month","Total Cost Analysis (Including Direct and Indirect Costs) — From enrollment to 12 months after screening"],"design_description":"NA · SINGLE GROUP · SCREENING · NONE","source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration (AMD)","Diabetic Retinopathy (DR)","The VeriSee AI-assisted diagnostic system","Data collection from the patient's clinical history"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06843499","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-06-02 to 2027-12-31","comparator":null,"confidence":"structured-source","population":"ALL · 20 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.815Z","intervention":["The VeriSee AI-assisted diagnostic system","Data collection from the patient's clinical history"],"participants":1000,"study_design":"NA · SINGLE GROUP · SCREENING · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Sensitivity — From screening to physician-confirmed diagnosis of AMD or DR, an average of 1 month","Specificity — From screening to physician-confirmed diagnosis of AMD or DR, an average of 1 month","Concordance — From screening to physician-confirmed diagnosis of AMD or DR, an average of 1 month","Total Cost Analysis (Including Direct and Indirect Costs) — From enrollment to 12 months after screening"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41451","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}